Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Gender and Development ; 30(1-2):283-309, 2022.
Article in English | Scopus | ID: covidwho-2050960


This paper examines the dynamics and implications of gendered austerity in Ecuador in the context of the fiscal consolidation framework recommended in the country's International Monetary Fund (IMF) loan programme, through three channels. First, that of the public health sector and the experiences of women public health workers. Second, that of unpaid care work and significant augmentations in home-based health care of family members as well as education support. And third, increases in consumer debt incurred by women through extractive short-term lenders. To illustrate the lived experiences of women, interviews were conducted with a leader of a nurses' union in the capital city of Quito and results collected from external published focus group surveys with women engaged in unpaid and paid care work as well as in community savings organizations. Two key theoretical frameworks are employed within feminist political economy. First, the social provisioning approach, where economic activity encompasses unpaid and paid work, human well-being is the yardstick of economic success, and power inequities, agency and economic outcomes are shaped by gender. Second, the literature on gender, care work and. © 2022 Oxfam KEDV.

Rev Neurol ; 72(s02): S1-S19, 2021 06 30.
Article in English, Spanish | MEDLINE | ID: covidwho-1335600


INTRODUCTION: After the European Headache Federation (EHF) Congress, renowned Spanish neurologists specialised in migraine presented the most significant latest developments in research in this field at the Post-EHF Meeting. DEVELOPMENT: The main data presented concerning the treatment of chronic and episodic migraine were addressed, with attention paid more specifically to those related to preventive treatments and real-life experience in the management of the disease. An important review was carried out of the new therapeutic targets and the possibilities they offer in terms of understanding the pathophysiology of migraine and its treatment. An update was also presented of the latest developments in the treatment of migraine with fremanezumab, a monoclonal antibody recently authorised by the European Medicines Agency. Participants were also given an update on the latest developments in basic research on the pathology, as well as an overview of the symptoms of migraine and COVID-19. Finally, the repercussions of migraine in terms of its burden on the care and economic resources of the health system were addressed, along with its impact on society. CONCLUSIONS: The meeting summarised the content presented at the 14th EHF Congress, which took place in late June/early July 2020.

TITLE: I Reunión Post-European Headache Federation: revisión de las novedades presentadas en el Congreso de la European Headache Federation de 2020.Introducción. Tras la celebración del congreso de la European Headache Federation (EHF), reconocidos neurólogos españoles expertos en el tratamiento de la migraña expusieron en la Reunión Post-EHF las principales novedades presentadas en el congreso y relacionadas con ese ámbito. Desarrollo. Se abordan los principales datos presentados relacionados con el tratamiento de la migraña crónica y episódica; concretamente, los relacionados con los tratamientos preventivos y la experiencia en vida real en el manejo de la enfermedad. Se hizo una importante revisión de las nuevas dianas terapéuticas y las posibilidades que ofrecen en cuanto al conocimiento de la fisiopatología de la migraña y su tratamiento. Asimismo, se hizo una actualización de las novedades presentadas en el tratamiento de la migraña con fremanezumab, anticuerpo monoclonal recientemente autorizado por la Agencia Europea de Medicamentos. Se hizo una actualización de las novedades en investigación básica en la patología, así como una relación de los síntomas de migraña y COVID-19. Finalmente, se abordaron las implicaciones de la migraña en la carga sanitaria asistencial y económica, y su impacto en la sociedad. Conclusiones. En la reunión se hizo un resumen del contenido presentado en el 14 Congreso de la EHF, que tuvo lugar a finales de junio y principios de julio de 2020.

Migraine Disorders/therapy , Antibodies, Monoclonal/therapeutic use , Congresses as Topic , Europe , Humans , Migraine Disorders/drug therapy , Migraine Disorders/etiology , Practice Guidelines as Topic
Journal of the American Society of Nephrology ; 31:305, 2020.
Article in English | EMBASE | ID: covidwho-984766


Background: Coronavirus 2019 (COVID-19) has infected millions of people worldwide, with the US reporting the most deaths. Many individuals are at high risk of disease progression, which may result in multi-organ failure and death. Risk factors include advanced age, cardiovascular disease (CVD), and chronic kidney disease (CKD). In addition, more than 40% of hospitalized patients develop acute kidney injury (AKI), with 20% of those requiring dialysis. Several therapeutic agents are in development, but patients with advanced CKD or those requiring immunosuppressive therapy are frequently excluded from participation in clinical trials. RBT-9, a proprietary formulation of stannous protoporphyrin, has organ protective effects, as demonstrated in animal models of kidney, liver, and lung injury. RBT-9 also has antiviral effects, as demonstrated in several enveloped viruses, including influenza, HCV, dengue, and yellow fever. A Phase 2, randomized, placebo-controlled study was designed to evaluate the effect of RBT-9 on progression of COVID-19 infection in high-risk individuals. Methods: This study will enroll up to 252 subjects with documented SARS-CoV-2 infection who are at risk of progression based on age (≥70 years) or comorbidities, including CKD (all stages, not on dialysis), CVD, chronic lung disease, diabetes mellitus, obesity, and mild hypoxemia. Subjects will be randomized 2:1 to receive a single dose of RBT-9 or placebo and will be followed for 56 days. Results: Study Objectives The primary objective is to evaluate the effect of RBT-9 versus placebo on clinical status measured using the 8-point World Health Organization (WHO) Ordinal Clinical Scale at Day 28. Secondary objectives include time to first occurrence of death from any cause or new/worsened organ dysfunction, survival, AKI incidence, new or worsening heart failure, hospitalization status and duration, ICU status, days on ventilator, vasopressor utilization or ventricular arrythmias. Conclusions: The organ protective and antiviral effects of RBT-9 warrant conduct of this clinical study, which is aimed at preventing progression to severe COVID-19 and organ failure. The first patient is expected to be enrolled in June 2020.